Merkel cell carcinoma: An Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients

Howle, Julie R.; Hughes, Michael; Gebski, Val; Veness, Michael J.

doi:10.1016/j.jaad.2011.07.029

Cited by 54 publications

(36 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgery is the mainstay of treatment for MCC when feasible. Outcome depends mainly on the early and wide excision [79], and on sequential radiotherapy, in order to avoid local relapse and/or progressive disease, as also confirmed from our personal observations. In this way, the role of SLNB is in our opinion fundamental also in stage I, given that size of lesion may not match the malignancy of the tumor.…”

Section: Discussionsupporting

confidence: 72%

Merkel Cell Carcinoma: A Retrospective Study on 48 Cases and Review of Literature

Cirillo

Vismarra

Cafaro

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. Fourty-eight patients with MCC were observed at the Rare Hormonal Tumors Group of Cremona Hospital, 15 of these with unknown primary site. Due to rarity of Merkel cell carcinoma, clinical experience is generally limited. Data from our series confirm the current recommendations. Wide surgical excision must be associated with radiotherapy also in early stages in order to avoid local relapse and the rapid progression of disease. In advanced stages chemotherapy is the standard despite the short duration of responses and poor quality of life. The data of our series, characterized by a high demand for second opinion, offer some insight about the real rarity of the tumor, the difficulty of managing of disease in our country secondary to a wrong cultural approach to the problem, the indiscriminate use of molecules unnecessary and often expensive, the lack of protocols, and the presence of guidelines often ignored. This results in very poor survival associated with a very low quality of life, requiring to find the right direction towards a correct management of disease.

show abstract

Section: Discussionsupporting

confidence: 72%

Merkel Cell Carcinoma: A Retrospective Study on 48 Cases and Review of Literature

Cirillo

Vismarra

Cafaro

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…24 Therefore, SLNB is advised if the patient can tolerate the additional operation. 25,26 Our data analysis confirmed that patients with positive nodes or no documented nodal evaluation had decreased DSS. Those patients who did undergo SLNB evaluation of nodal disease had a survival benefit with completion lymph node dissection.…”

Section: Commentssupporting

confidence: 68%

Merkel cell carcinoma: what makes a difference?

Tseng

Dhungel

Mills

et al. 2015

The American Journal of Surgery

View full text Add to dashboard Cite

“…Increasing stage, age > 70 years, male gender, lymphovascular invasion and a high mitotic index may all contribute to a higher risk of locoregional recurrence [20e22]. An increasing number of metastatic nodes is associated with a significantly worse overall survival (hazard ratio 4.9, 1.15e21.13, P ¼ 0.03) [23].…”

Section: Risk Factors For Recurrencementioning

confidence: 99%